泊沙康唑预防和治疗侵袭性真菌病.pptVIP

* * Posaconazole is an extended-spectrum triazole with in vitro activity against a wide range of pathogenic moulds and yeasts, from Aspergillus to the Zygomycetes. Posaconazole (Noxafil?) oral suspension was approved for use in the European Union in October 2005 for the following indications: Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B Chromoblastomycosi